-
脑梗死是临床上常见的脑血管疾病,好发于老年人群,约15%病人会并发认知功能障碍,严重影响病人的身体健康和日常生活,其作为唯一可以人为预防及提早干预的认知障碍性疾病已经引起广泛关注,寻找有效的治疗药物成为关键。阿托伐他汀是目前临床最主流应用的调脂药物,在心脑血管疾病的一级、二级预防及治疗中已广泛应用[1-2]。炎症反应在缺血性脑血管病中发挥着重要的作用,Toll样受体4(TLR4)是一种进化保守的模式识别受体,有研究[3]发现,阿尔茨海默病病人脑组织及外周血中TLR4表达升高,表明TLR4参与阿尔茨海默病的病理过程,TLR4与认知障碍的发生及发展存在相关性。本研究旨在探讨阿托伐他汀对老年脑梗死合并认知障碍病人的临床作用及相关机制。现作报道。
-
治疗前,2组病人血脂指标差异无统计学意义(P>0.05)。治疗后,2组TC、TG、LDL-C、HDL-C与治疗前比较差异均有统计学意义(P < 0.05~P < 0.01),且观察组TC、TG、LDL-C低于对照组,HDL-C高于对照组(P < 0.01)(见表 1)。
分组 n TC TG LDL-C HDL-C 治疗前 对照组 49 5.45±0.68 2.15±0.37 2.23±0.32 0.97±0.09 观察组 49 5.51±0.79 2.11±0.35 2.19±0.45 0.96±0.10 t — 0.40 0.55 0.51 0.52 P — >0.05 >0.05 >0.05 >0.05 治疗后 对照组 49 4.63±0.63** 1.92±0.29** 2.09±0.27* 1.16±0.13** 观察组 49 4.06±0.53** 1.64±0.28** 1.78±0.21** 1.31±0.15** t — 4.85 4.86 6.34 5.29 P — < 0.01 < 0.01 < 0.01 < 0.01 组内配对t检验:与治疗前比较*P < 0.05,**P < 0.01 表 1 2组病人治疗前后血脂水平比较(x±s; mmol/L)
-
治疗前,2组ox-LDL、hs-CRP、TGF-β1、TLR4、NF-κB、TNF-α和IL-6差异均无统计学意义(P>0.05)。治疗后,2组ox-LDL、hs-CRP、TGF-β1、TLR4、NF-κB、TNF-α和IL-6与治疗前比较差异均有统计学意义(P < 0.01),且观察组ox-LDL、hs-CRP、TLR4、NF-κB、TNF-α和IL-6低于对照组,TGF-β1高于对照组(P < 0.01)(见表 2)。
分组 n ox-LDL/(ng/mL) hs-CRP/(mg/L) TGF-β1/(pg/mL) TLR4 NF-κB/(ng/mL) TNF-α/(mg/L) IL-6/(ng/L) 治疗前 对照组 49 121.72±14.31 8.35±1.46 189.50±20.23 5.12±0.65 22.13±4.12 15.86±2.63 26.83±5.42 观察组 49 121.45±13.84 8.41±1.57 190.49±21.20 5.14±0.71 22.05±3.96 15.91±2.57 26.79±4.16 t — 0.10 0.20 0.24 0.15 0.10 0.10 0.04 P — >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 治疗后 对照组 49 99.24±10.28** 4.27±1.19** 204.71±15.18** 4.06±0.37** 17.67±1.89** 11.02±1.78** 22.47±6.01** 观察组 49 83.06±11.17** 2.52±0.83** 231.93±18.24** 2.31±0.15** 13.28±1.73** 8.26±1.45** 19.20±4.38** t — 7.46 8.44 8.03 30.68 11.99 8.42 3.08 P — < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 组内配对t检验:与治疗前比**P < 0.01 表 2 2组治疗前后炎症因子等及TLR4水平比较(x±s)
-
治疗前,2组病人MMSE、MoCA评分比较差异均无统计学意义(P>0.05);治疗后,2组MMSE、MoCA均较治疗前提高,且观察组高于对照组,差异有统计学意义(P < 0.01)(见表 3)。
分组 n MMSE评分 MoCA评分 治疗前 对照组 49 16.15±2.28 17.56±1.87 观察组 49 16.09±2.16 17.74±1.96 t — 0.13 0.56 P — >0.05 >0.05 治疗后 对照组 49 20.07±1.36** 21.37±1.15** 观察组 49 24.38±1.54** 25.01±1.64** t — 14.64 12.72 P — < 0.01 < 0.01 组内配对t检验:与治疗前比较**P < 0.01 表 3 2组病人治疗前后认知功能比较(x±s; 分)
-
2组病人不良反应:肝肾功能异常、头晕头痛、皮疹、肌痛、胃肠道反应的发生率比较差异均无统计学意义(P>0.05)(见表 4)。
分组 n 肝肾功能异常 头晕头痛 皮疹 肌痛 胃肠道反应 对照组 49 2(4.1) 4(8.2) 2(4.1) 2(4.1) 3(6.1) 观察组 49 1(2.0) 2(4.1) 1(2.0) 1(2.0) 2(4.1) χ2 — 0.34 0.71 0.34 0.34 0.21 P — >0.05 >0.05 >0.05 >0.05 >0.05 表 4 2组病人不良反应比较[n; 百分率(%)]
阿托伐他汀对老年脑梗死病人TLR4信号通路及认知功能的影响
Effect of atorvastatin on TLR4 signaling pathway and cognitive function in elderly patients with cerebral infarction
-
摘要:
目的探讨老年脑梗死合并认知功能障碍病人Toll样受体4(TLR4)信号通路的变化,以及阿托伐他汀在调节该通路中的作用及对认知功能的影响。 方法选择老年脑梗死合并认知功能障碍病人98例,随机分为观察组和对照组,各49例。对照组在常规治疗基础上,应用阿司匹林肠溶片治疗,观察组在常规治疗基础上采用阿司匹林肠溶片联合阿托伐他汀治疗,分别于治疗前及治疗后6个月比较2组病人认知功能状况、血清氧化型低密度脂蛋白(ox-LDL)、转化生长因子-β1(TGF-β1)、超敏C反应蛋白(hs-CRP)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)、TLR4和核转录因子(NF)-κB、肿瘤坏死因子(TNF)-α和白细胞介素(IL)-6的表达情况以及不良反应发生情况。 结果治疗后,2组TC、TG、LDL-C、HDL-C、ox-LDL、hs-CRP、TGF-β1、TLR4、NF-κB、TNF-α和IL-6与治疗前比较差异均有统计学意义(P < 0.05~P < 0.01);且观察组TC、TG、LDL-C、ox-LDL、hs-CRP、TLR4、NF-κB、TNF-α和IL-6低于对照组,HDL-C、TGF-β1高于对照组(P < 0.01)。治疗后,2组MMSE、MoCA评分均较治疗前提高,且观察组高于对照组(P < 0.01)。2组病人不良反应:肝肾功能异常、头晕头痛、皮疹、肌痛、胃肠道反应的发生率比较差异均无统计学意义(P>0.05)。 结论TLR4信号通路参与了老年脑梗死合并认知功能障碍的发生过程,阿托伐他汀治疗可通过调节TLR4信号通路对其发挥脑保护作用。 -
关键词:
- 脑梗死 /
- 阿托伐他汀 /
- 认知功能障碍 /
- Toll样受体4信号通路
Abstract:ObjectiveTo investigate the changes of Toll-like receptor 4 (TLR4) signaling pathway in elderly patients with cerebral infarction complicated with cognitive dysfunction, and the role of atorvastatin in regulating this pathway and its influence on cognitive function. MethodsA total of 98 elderly patients with cerebral infarction and cognitive dysfunction were randomly divided into the observation group and control group(49 cases in each group). The control group was treated with aspirin enteric-coated tablets on the basis of routine treatment, while the observation group was treated with aspirin enteric-coated tablets combined with atorvastatin on the basis of routine treatment. The cognitive function, serum oxidized low-density lipoprotein(ox-LDL), transforming growth factor-β1(TGF-β1), high-sensitivity C reactive protein(hs-CRP), total cholesterol (TC), triglyceride(TG), low-density lipoprotein cholesterol(LDL-C) and high-density lipoprotein cholesterol(HDL-C), TLR4 and nuclear transcription factor(NF)-κB, tumor necrosis factor(TNF)-α and interleukin(IL)-6 and the occurrence of adverse reactions in the two groups were compared before and six months after treatment. ResultsAfter treatment, there were statistically significant differences in the levels of TC, TG, LDL-C, HDL-C, ox-LDL, hs-CRP, TGF-β1, TLR4, NF-κB, TNF-α and IL-6 between the two groups compared with before treatment(P < 0.05 to P < 0.01);the levels of TC, TG, LDL-C, ox-LDL, hs-CRP, TLR4, NF-κB, TNF-α and IL-6 in the observation group were lower than those in the control group, and the levels of HDL-C, TGF-β1 were higher than those in the control group(P < 0.01). After treatment, the MMSE and MoCA scores in the two groups were improved compared with those before treatment, and which in the observation group was higher than that in the control group(P < 0.01). There were no significant differences in the incidence of adverse reactions such as abnormal liver and kidney function, dizziness and headache, rash, myalgia and gastrointestinal reactions between two groups(P>0.05). ConclusionsThe TLR4 signaling pathway is involved in the occurrence of cerebral infarction combined with cognitive dysfunction in elderly, and atorvastatin can exhibit the cerebral protective role in regulating TLR4 signaling pathway. -
表 1 2组病人治疗前后血脂水平比较(x±s; mmol/L)
分组 n TC TG LDL-C HDL-C 治疗前 对照组 49 5.45±0.68 2.15±0.37 2.23±0.32 0.97±0.09 观察组 49 5.51±0.79 2.11±0.35 2.19±0.45 0.96±0.10 t — 0.40 0.55 0.51 0.52 P — >0.05 >0.05 >0.05 >0.05 治疗后 对照组 49 4.63±0.63** 1.92±0.29** 2.09±0.27* 1.16±0.13** 观察组 49 4.06±0.53** 1.64±0.28** 1.78±0.21** 1.31±0.15** t — 4.85 4.86 6.34 5.29 P — < 0.01 < 0.01 < 0.01 < 0.01 组内配对t检验:与治疗前比较*P < 0.05,**P < 0.01 表 2 2组治疗前后炎症因子等及TLR4水平比较(x±s)
分组 n ox-LDL/(ng/mL) hs-CRP/(mg/L) TGF-β1/(pg/mL) TLR4 NF-κB/(ng/mL) TNF-α/(mg/L) IL-6/(ng/L) 治疗前 对照组 49 121.72±14.31 8.35±1.46 189.50±20.23 5.12±0.65 22.13±4.12 15.86±2.63 26.83±5.42 观察组 49 121.45±13.84 8.41±1.57 190.49±21.20 5.14±0.71 22.05±3.96 15.91±2.57 26.79±4.16 t — 0.10 0.20 0.24 0.15 0.10 0.10 0.04 P — >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 >0.05 治疗后 对照组 49 99.24±10.28** 4.27±1.19** 204.71±15.18** 4.06±0.37** 17.67±1.89** 11.02±1.78** 22.47±6.01** 观察组 49 83.06±11.17** 2.52±0.83** 231.93±18.24** 2.31±0.15** 13.28±1.73** 8.26±1.45** 19.20±4.38** t — 7.46 8.44 8.03 30.68 11.99 8.42 3.08 P — < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 < 0.01 组内配对t检验:与治疗前比**P < 0.01 表 3 2组病人治疗前后认知功能比较(x±s; 分)
分组 n MMSE评分 MoCA评分 治疗前 对照组 49 16.15±2.28 17.56±1.87 观察组 49 16.09±2.16 17.74±1.96 t — 0.13 0.56 P — >0.05 >0.05 治疗后 对照组 49 20.07±1.36** 21.37±1.15** 观察组 49 24.38±1.54** 25.01±1.64** t — 14.64 12.72 P — < 0.01 < 0.01 组内配对t检验:与治疗前比较**P < 0.01 表 4 2组病人不良反应比较[n; 百分率(%)]
分组 n 肝肾功能异常 头晕头痛 皮疹 肌痛 胃肠道反应 对照组 49 2(4.1) 4(8.2) 2(4.1) 2(4.1) 3(6.1) 观察组 49 1(2.0) 2(4.1) 1(2.0) 1(2.0) 2(4.1) χ2 — 0.34 0.71 0.34 0.34 0.21 P — >0.05 >0.05 >0.05 >0.05 >0.05 -
[1] OESTERLE A, LAUFS U, LIAO JK. Pleiotropic effects of statins on the cardiovascular system[J]. Circ Res, 2017, 120(1): 229. doi: 10.1161/CIRCRESAHA.116.308537 [2] ALFONSI JE, HEGELE RA, GRYN SE. Pharmacogenetics of lipid-lowering agents: precision or indecision medicine?[J]. Curr Atheroscler Rep, 2016, 18(5): 24. doi: 10.1007/s11883-016-0573-6 [3] YANG J, WISE L, FUKUCHI KI. TLR4 Cross-talk with NLRP3 inflammasome and complement signaling pathways in Alzheimer's disease[J]. Front Immunol, 2020, 23(11): 724. [4] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国各类主要脑血管病诊断要点2019[J]. 中华神经科杂志, 2019, 52(9): 710. [5] 冯玉婧, 袁建新, 杨秀平, 等. 老年腔隙性脑梗死病人尿液AD7c-NTP及血清C反应蛋白与血管性轻度认知障碍的相关性[J]. 蚌埠医学院学报, 2021, 46(7): 866. [6] 周汝娟, 郭民旺, 汪小荣, 等. 干预高同型半胱氨酸水平对脑梗死后病人认知功能的影响[J]. 蚌埠医学院学报, 2017, 42(8): 1064. [7] WAHID D, RABBANI H, INAM A, et al. A hemispheric comparison of cognitive dysfunction and sleep quality impairment in Middle Cerebral Artery infarction[J]. Pak J Med Sci, 2020, 36(3): 511. [8] 宁晓明, 刘建妮, 曹金强. 中西药联合辅助治疗脑梗死后血管性痴呆的临床疗效及安全性[J]. 临床合理用药杂志, 2021, 14(25): 68. [9] 陈建煌, 贝玉章, 卜桂文, 等. 丁苯酞联合奥拉西坦治疗急性脑梗死合并认知功能障碍的临床疗效研究[J]. 临床合理用药杂志, 2021, 14(27): 39. [10] ANDRESEN L, THEODOROU K, GRUNEWALD SS, et al. Evaluation of the therapeutic potential of anti-TLR4-Antibody MTS510 in experimental stroke and significance of different routes of application[J]. PLoS One, 2016, 11(2): e0148428. doi: 10.1371/journal.pone.0148428 [11] CHEN S, YIN W, BI K, et al. MicroRNA 497 attenuates cerebral infarction in patients via the TLR4 and CREB signaling pathways[J]. Int J Mol Med, 2018, 42(1): 547. [12] HUANG L, CHEN C, ZHANG X, et al. Neuroprotective effect of curcumin against cerebral ischemia-reperfusion via mediating autophagy and inflammation[J]. J Mol Neurosci, 2018, 64(1): 129. doi: 10.1007/s12031-017-1006-x [13] BADSHAH H, ALI T, KIM MO. Osmotin attenuates LPS-induced neuroinflammation and memory impairments via the TLR4/NFκB signaling pathway[J]. Sci Rep, 2016, 20(6): 24493. [14] CUI W, SUN C, MA Y, et al. Inhibition of TLR4 Induces M2 microglial polarization and provides neuroprotection via the NLRP3 inflammasome in Alzheimer's disease[J]. Front Neurosci, 2020, 14: 444. doi: 10.3389/fnins.2020.00444 [15] SHI CX, JIN J, WANG XQ, et al. Sevoflurane attenuates brain damage through inhibiting autophagy and apoptosis in cerebral Ischemia-reperfusion rats[J]. Mol Med Rep, 2020, 21(1): 123. [16] ZHANG Z, QIN P, DENG Y, et al. The novel estrogenic receptor GPR30 alleviates ischemic injury by inhibiting TLR4-mediated microglial inflammation[J]. J Neuroinflammation, 2018, 15(1): 206. doi: 10.1186/s12974-018-1246-x [17] 韩蕊. 阿托伐他汀对于高龄冠状动脉慢血流患者血清炎症指标、血管内皮功能和疗效的影响[J]. 中国医药指南, 2018, 16(2): 157. [18] YU Q, LI G, DING Q, et al. Irisin protects brain against ischemia/reperfusion injury through suppressing TLR4/MyD88 pathway[J]. Cerebrovasc Dis, 2020, 49(4): 346. doi: 10.1159/000505961 [19] WU LR, LIU L, XIONG XY, et al. Vinpocetine alleviate cerebral ischemia/reperfusion injury by down-regulating TLR4/MyD88/NF-κB signaling[J]. Oncotarget, 2017, 8(46): 80315. doi: 10.18632/oncotarget.20699 [20] FENG W. Tectorigenin attenuates cognitive impairments in mice with chronic cerebral ischemia by inhibiting the TLR4/NF-κB signaling pathway[J]. Biosci Biotechnol Biochem, 2021, 85(7): 1665. doi: 10.1093/bbb/zbab086 [21] HU YH, WANG Y, WANG F, et al. SPOP negatively regulates Toll-like receptor-induced inflammation by disrupting MyD88 self-association[J]. Cell Mol Immunol, 2021, 18(7): 1708. doi: 10.1038/s41423-020-0411-1 [22] GUO SX, LI WY, ZHOU G, et al. Polysaccharide of Atractylodes macrocephala Koidz regulates LPS-mediated mouse hepatitis through the TLR4-MyD88-NFκB signaling pathway[J]. Int Immunopharmacol, 2021, 98: 107692. doi: 10.1016/j.intimp.2021.107692